Inactivation of TIF1γ Cooperates with KrasG12D to Induce Cystic Tumors of the Pancreas by Vincent, David F. et al.
Inactivation of TIF1c Cooperates with Kras
G12D to Induce
Cystic Tumors of the Pancreas
David F. Vincent
1,2,3,5., Kai-Ping Yan
4.¤, Isabelle Treilleux
5, Fabien Gay
6, Vanessa Arfi
1,2,3,5, Bastien
Kaniewsky
1,2,3,5, Julien C. Marie
7, Florian Lepinasse
2,6,8, Sylvie Martel
1,3,5, Sophie Goddard-Leon
5, Juan L.
Iovanna
9, Pierre Dubus
10, Ste ´phane Garcia
9, Alain Puisieux
1,2,5, Ruth Rimokh
1,2, Nabeel Bardeesy
11,
Jean-Yves Scoazec
2,6,8,R e ´gine Losson
4, Laurent Bartholin
1,2,3,5*
1INSERM, U590, IFR62, Lyon, France, 2Univ Lyon, Lyon, France, 3INSERM ‘‘Avenir’’ group, Lyon, France, 4IGBMC, Strasbourg, Illkirch-Cedex, France, 5Centre Le ´on Be ´rard,
Lyon, France, 6INSERM, U865, Faculte ´ Laennec, Lyon, France, 7INSERM, U758, Lyon, France, 8Hospices Civils de Lyon, Ho ˆpital Edouard Herriot, Lyon, France, 9INSERM,
U624, Marseille, France, 10EA 2406, Univ Bordeaux, France, 11Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United
States of America
Abstract
Inactivation of the Transforming Growth Factor Beta (TGFb) tumor suppressor pathway contributes to the progression of
Pancreatic Ductal AdenoCarcinoma (PDAC) since it is inactivated in virtually all cases of this malignancy. Genetic lesions
inactivating this pathway contribute to pancreatic tumor progression in mouse models. Transcriptional Intermediary Factor
1 gamma (TIF1c) has recently been proposed to be involved in TGFb signaling, functioning as either a positive or negative
regulator of the pathway. Here, we addressed the role of TIF1c in pancreatic carcinogenesis. Using conditional Tif1c
knockout mice (Tif1c
lox/lox), we selectively abrogated Tif1c expression in the pancreas of Pdx1-Cre;Tif1c
lox/lox mice. We also
generated Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice to address the effect of Tif1c loss-of-function in precancerous lesions
induced by oncogenic Kras
G12D. Finally, we analyzed TIF1c expression in human pancreatic tumors. In our mouse model, we
showed that Tif1c was dispensable for normal pancreatic development but cooperated with Kras activation to induce
pancreatic tumors reminiscent of human Intraductal Papillary Mucinous Neoplasms (IPMNs). Interestingly, these cystic
lesions resemble those observed in Pdx1-Cre;LSL-Kras
G12D;Smad4
lox/lox mice described by others. However, distinctive
characteristics, such as the systematic presence of endocrine pseudo-islets within the papillary projections, suggest that
SMAD4 and TIF1c don’t have strictly redundant functions. Finally, we report that TIF1c expression is markedly down-
regulated in human pancreatic tumors by quantitative RT–PCR and immunohistochemistry supporting the relevance of
these findings to human malignancy. This study suggests that TIF1c is critical for tumor suppression in the pancreas, brings
new insight into the genetics of pancreatic cancer, and constitutes a promising model to decipher the respective roles of
SMAD4 and TIF1c in the multifaceted functions of TGFb in carcinogenesis and development.
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Introduction
Pancreatic Ductal AdenoCarcinoma (PDAC), characterized by
a ductal cell-type differentiation pattern, is the most common type
of pancreatic cancer, accounting for more than 85% of pancreatic
neoplasms. PDAC is the fourth leading cause of cancer-related
mortality and carries an overall 5-year-survival rate of less than
5% [1]. The poor outcome of these patients is due to late diagnosis
and resistance to current therapies. PDAC appears to arise from
precursor lesions known as Pancreatic Intraepithelial Neoplasia
(PanINs) or from two types of cystic tumors: Mucinous Cystic
Neoplasms (MCNs) and Intraductal Papillary Mucinous Neo-
plasms (IPMNs) [2]. Mucinous cystic neoplasms are cysts lined by
mucin-producing epithelial cells usually associated with an
ovarian-type of stroma. These cysts do not communicate with
the larger pancreatic ducts. IPMNs form intraductal papillary
projections replacing the normal duct epithelium, secrete mucin,
and communicate with ducts. IPMNs are currently classified
according to their pattern of apparent histological differentiation
into three main subtypes: intestinal (with the neoplastic epithelium
resembling the intestinal epithelium), the most frequent, pancre-
atobiliary and gastric [3].
Recurrent genetic alterations have been identified in human
PDAC [4,5]. Sporadic cases, which represent the vast majority of
PDAC, are associated with activation of the KRAS oncogene
(.90% of cases) and inactivation of the INK4A/ARF (.80% of
cases), TP53 (.50% of cases) and SMAD4/DPC4 (.50% of cases)
tumor suppressors. Inherited pancreatic cancers represent approx-
PLoS Genetics | www.plosgenetics.org 1 July 2009 | Volume 5 | Issue 7 | e1000575imately 5–10% of all pancreatic cancers. In a high proportion of
familial pancreatic cancers, the genetic alterations causing the
disease are still unknown. However, several germinal mutations
associated with complex familial syndromes have been shown to
significantly increase the risk of developing pancreatic cancer
(BRCA2, INK4A, STK11/LKB1, PRSS1, hMLH1 and hMSH2) [1,6].
In the last five years, a series of genetically engineered mouse
models of PDAC have been developed based on these signature
gene mutations [7]. For instance, expression of a constitutively
active Kras mutant protein (Kras
G12D or Kras
G12V) induces
PanINs that eventually progress towards PDAC [8,9,10]. Kras
activated mutants act in concert with inactivation of the p53 [11],
Ink4A/Arf [12,13], and TbRII [14] tumor suppressors to
accelerate development of PDAC. These models and others
[15–19] support the concept that progression towards invasive
PDAC involves emergence from different precancerous lesions
(PanINs, MCNs and IPMNs) depending on the associated genetic
alterations.
The TGFb pathway appears to be of particular importance to
PDAC tumor suppression, since it is inactivated in virtually all
cases of this malignancy [20], and since genetic lesions inactivating
the pathway—inactivation of Smad4 or TbRII and over-expression
of inhibitory Smad7— contribute to pancreatic tumor progression
in mouse models [14,21–24]. Transforming growth factor beta
(TGFb) is a secreted polypeptide belonging to a wide family of
cytokines and growth factors including TGFbs, Bone Morphoge-
netic Proteins (BMPs) and activins [25,26]. Upon binding to its
receptors, TGFb triggers phosphorylation of the SMAD2 and
SMAD3 transcription factors. Phosphorylated SMAD2 and
SMAD3 then interact with SMAD4. The SMAD2/3/4 complex
accumulates within the nucleus, binds to DNA and activates the
transcription of target genes leading to proliferative arrest or
apoptosis of epithelial cells.
Transcriptional Intermediary Factor 1 gamma (also named
TIF1c/TRIM33/RFG7/PTC7/Ectodermin) [27,28] appears to
contribute to TGFb signaling, although its precise functional role
is not clear. Some data point toward TIF1c as a negative regulator
of the pathway through its capacity to mono-ubiquinate SMAD4
and limit SMAD4 nuclear accumulation [29,30,31]. In contrast,
other studies have suggested that TIF1c plays an important
positive role in transducing TGFb signaling through its interaction
with SMAD2 and SMAD3 [32].
Here we wished to determine whether TIF1c contributes to
tumorigenesis consistent with a function within the TGFb
signaling pathway. We have focused on pancreatic exocrine
tumors based on the prominent role played by TGFb signaling in
these malignancies. Using a conditional mouse strain, we show for
the first time that Tif1c is an important gene whose loss of function
cooperates with Kras
G12D activation to induce cystic pancreatic
tumors resembling human IPMNs. We also report that TIF1c
expression is down-regulated in human PDAC and some types of
precursor lesions, supporting the relevance of our mouse model to
human malignancy.
Results/Discussion
To selectively abrogate Tif1c expression in the pancreas, we
crossed conditional Tif1c knockout mice [33] with Pdx1-Cre mice
[34]. Pdx1 is a gene expressed in the common progenitor to all
pancreatic lineages during early embryogenesis, hence Pdx1-Cre
transgenic mice exhibit recombination of floxed alleles in
pancreatic cells from all lineages (endocrine, acinar, centroacinar
and ductal cells) [35]. Pdx1-Cre;Tif1c
lox/lox animals were born at
expected ratios and showed normal lifespan without obvious
developmental or physiological alterations. Live imaging tech-
niques (Positron Emission Tomography, PET and Magnetic
Resonance Imaging, MRI), histological techniques (immunodetec-
tion of insulin, glucagon, PPY, chymotrypsine, F4/80, CD3,
MPO), metabolic tests (glucose tolerance) did not reveal any
significant differences between wild-type and Pdx1-Cre;Tif1c
lox/lox
littermates (n.20, between 3 weeks and 2 years of age) (data not
shown). As expected, immunohistochemistry experiments showed
that Tif1c was expressed in the nuclei of pancreatic cells in wild-
type mice and that this staining was lost in the Pdx1-Cre;Tif1c
lox/lox
pancreas (Figure S1). In all, these observations show that Tif1c is
dispensable for normal pancreatic development and function in
the mouse.
Activating KRAS mutations occur early in human PDAC
pathogenesis and give rise to slowly progressing PanINs in mouse
models [8,10,12]. We then asked whether Tif1c inactivation could
modify the phenotype or latency of the pancreatic lesions induced
by Kras
G12D. To that end, we generated Pdx1-Cre;LSL-Kras
G12D;
Tif1c
lox/lox mice (n=12, Table S1). All animals looked healthy at
the time they were euthanized (the oldest animal was sacrificed at
the age of 189 days). Since pancreatic lesions are often
asymptomatic, we decided to explore in vivo the pancreas of these
mutant mice (n=4) by PET and MRI imaging techniques. Pdx1-
Cre;LSL-Kras
G12D;Ink4A/Arf
lox/lox mice, which exhibit rapid PDAC
progression, were also employed in these studies. Strikingly, MRI
imaging performed on Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox animals
revealed an hypertrophic pancreas with multifocal cystic lesions
exhibiting T2 hypersignals visible as early as 7 weeks after birth
(T2 weighted scans allow detection of cysts as they are sensitive to
water content) (Figure 1B). Such lesions were absent in the
pancreas of wild-type and Pdx1-Cre;LSL-Kras
G12D animals
(Figure 1A) and were clearly different from those observed in
Pdx1-Cre;LSL-Kras
G12D;Ink4A/Arf
lox/lox mice, which harbor solid
tumors exhibiting a T1 isosignals (T1 weighed scans allow
detection of solid tumors) (Figure 1C). PET imaging did not show
significant increased metabolic activity in the abdomen of wild-
type (Figure 1D) and Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice
(Figure 1E) whereas Pdx1-Cre;LSL-Kras
G12D;Ink4A/Arf
lox/lox mice
had abdominal lesions with readily detectable metabolic activity
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G12D;
Tif1c
lox/lox pancreas confirmed the presence of numerous cysts
affecting the entire organ without macroscopic evidence of
invasive carcinoma (Figure 1H and Figure S2) whereas the
pancreas of Pdx1-Cre;LSL-Kras
G12D;Ink4A/Arf
lox/lox mice was invad-
ed by a firm and homogeneous mass (Figure 1I) and the pancreas
from wild-type or Pdx1-Cre;LSL-Kras
G12D animals had a normal
macroscopic appearance (Figure 1G). The size of these cysts
observed in the pancreas from Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox
was variable and most of them contained papillary projections
(Figure 1K). These lesions clearly contrast with the invasive tumors
of ductal morphology identified as PDAC in the pancreas of Pdx1-
Cre;LSL-Kras
G12D;Ink4A/Arf
lox/lox (Figure 1L). The histological
analysis of the 12 Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox animals (Table
S1) revealed the presence of cystic lesions in 100% of these mice,
such cysts being never observed in Pdx1-Cre;LSL-Kras
G12D or wild
type control animals. Quantitative analysis revealed that the area
occupied by the abnormal pancreas exceeded 50% by the age 6
weeks in 6/7 Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice whereas it
represented less than 20% in 6/6 Pdx1-Cre;LSL-Kras
G12D mice
(Table S1). Collectively these data demonstrate that inactivation of
Tif1c actively cooperates with activated Kras
G12D to induce cystic
tumors of the pancreas.
To carefully compare the pancreatic lesions observed in Pdx1-
Cre;LSL-Kras
G12D;Tif1c
lox/lox with the Pdx1-Cre;LSL-Kras
G12D con-
trols, we performed a sequential histological analysis of pancreas
from animals (n=12) euthanized at different ages (Table S1).
Contrary to wild-type mice (Figure 2A–2D), Pdx1-Cre;LSL-Kras
G12D
mice gradually developed focal PanINs by the age of about 10
weeks (Figure 2E–2H). Strikingly, in Pdx1-Cre;LSL-Kras
G12D;Tif1-
c
lox/lox pancreas, PanINs, signs of acute inflammation as well as
enlarged and dilated ductal structure resembling budding cysts
were observed as early as 3 weeks of age (Figure 2I and Figure S3).
At later time points, inflammatory tissue and PanINs were mainly
Figure 1. Homozygous deletion of Tif1c cooperates with activated Kras
G12D mutation to induce cystic tumors of the pancreas.
Magnetic Resonance Imaging (MRI) (A–C). Positron Emission Tomography (PET) (D–F). Gross anatomy of the pancreas after dissection (G–I).
Hematoxylin Phloxine Saffron (HPS) staining of pancreas sections (J–L). Acinar tissue (stars), scattered endocrine islets (arrow) and exocrine ducts
(arrowhead). When notified, pancreas is circled in red dashed lines. Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox used in this experiment was 154 days old and
representative of the 4 mice we analyzed at the age of 18–27 weeks.
doi:10.1371/journal.pgen.1000575.g001
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larger size (Figure 2J–2L). Microscopic examination revealed that
the lining of the cystic structures characteristically found in the
pancreas from Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice was formed
by epithelial cells with a cuboidal or cylindrical morphology.
These cells formed numerous thick papillary projections in the cyst
lumen. The axis of these projections usually contained masses of
small monomorphic cells with an endocrine morphology (Insets in
Figure 2I–2L).
We performed immunohistochemical studies to characterized
the evolving pancreatic lesions in these mice. We observed staining
for chymotrypsin and insulin, which decreased with age, indicating
areplacementofexocrineandendocrinecomponents,togetherwith
abnormal ductal structures in Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox
mice (Figure 3). There was a notable disappearance of well-
organized endocrine islets with age coinciding with the accumula-
tion of endocrine cells within the papillary projections bulging
within the lumen of the cysts.
To more precisely identify the nature of these lesions, several
lineage markers were explored by immunohistochemistry. We
first verified that Tif1c expression was lost in pancreatic ducts
from Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice (Figure 4E) com-
pared to normal observed ducts in wild-type mice (Figure 4A). In
the normal pancreas, cytokeratin 19 (CK19) is specifically
expressed by ductal cells lining the secretory ducts (Figure 4B).
We verified that most of the epithelial cells lining the cystic lesions
observed in Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice were positive
for CK19 (Figure 4F); this is consistent with a ductal phenotype
for these cells. However, in contrast to the cells lining the normal
secretory ducts (Figure 4C), many cells lining the cysts were
mucus-secreting and stained for Alcian blue (Figure 4G). The
cells with an endocrine appearance present within the intra-cystic
papillary projections were CK19 and Alcian blue negative. There
was no evidence of ovarian-type stroma or of invasive or
microinvasive carcinoma, even on serial sections, suggesting that
these cystic tumors resemble human IPMNs. In all, the cystic
lesions observed in Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice show
distinctive characteristics, including the presence of intra-
epithelial endocrine pseudo-islets, suggestive of a mixed, endo-
crine-exocrine, lesion [7].
TIF1c has recently been proposed to be involved in TGFb
signaling [29,32]. The resemblance between the cystic lesions
(either IPMNs [21,23] or MCNs [22]) observed in Pdx1-Cre;LSL-
Kras
G12D;Smad4
lox/lox mice, and the cystic lesions we observed in the
Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice, reinforces an active role of
TIF1c in TGFb signaling. However, we cannot rule out the
possibility that TIF1c could also be involved in other signaling
pathways. Interestingly, we observed that Smad4 expression was
almost undetectable in epithelial cells lining the papillary
projections observed in Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice
whereas it was detectable in epithelial cells lining the cysts
(Figure 4H) or in normal ducts (Figure 4D). IPMNs observed in
Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice always contain a significant
endocrine component, a rare event in IPMNs observed in Pdx1-
Cre;LSL-Kras
G12D;Smad4
lox/lox mice [21,23]. This observation sug-
gests that TIF1c and SMAD4 could differentially regulate
endocrine versus exocrine differentiation in a context of an
activated KRAS oncogenic protein.
Figure 2. Inactivation of Tif1c accelerates activated Kras
G12D–mediated pancreatic neoplasia. Sections of wild-type (A–D), Pdx1-Cre;LSL-
Kras
G12D (E–H) and Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox (I–L) pancreas from mice at different ages were stained with HPS. Number of mice: 3 weeks, n=3;
6–13 weeks, n=5; 18–27 weeks, n=4. Inset pictures: Higher magnification.
doi:10.1371/journal.pgen.1000575.g002
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PLoS Genetics | www.plosgenetics.org 4 July 2009 | Volume 5 | Issue 7 | e1000575Figure 3. Endocrine and exocrine compartments destruction in the pancreas of Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice. Wild-type (A–C9)
and Pdx1-Cre; LSL-Kras
G12D; Tif1c
lox/lox (D–L9) pancreas sections were stained with HPS (A,D,G,J), immuno-revealed either with an anti-chymotrypsin
antibody (B,E,H,K) or an anti-insulin antibody (C,F,I,L and C9,F9,I9,L9 that represent the boxed region in C,F,I,L at a higher magnification). For Pdx1-
Cre;LSL-Kras
G12D;Tif1c
lox/lox mice, analysis were performed at different ages. Number of mice: 3 weeks, n=3; 6–13 weeks, n=5; 18–27 weeks, n=4.
Boxes: Higher magnification. The pictures show one representative mouse for each group.
doi:10.1371/journal.pgen.1000575.g003
Figure 4. Immunophenotyping of pancreas cysts observed in Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice. Wild-type (A–D) and Pdx1-Cre;Tif1c
lox/lox;
LSL-Kras
G12D (E–H) pancreas sections were stained to detect glandular cells (CK19), mucus-secreting cells (Alcian Blue), Tif1c and Smad4. The pictures
show one representative mouse at the age of 22 weeks.
doi:10.1371/journal.pgen.1000575.g004
TIF1c Mutation and Pancreatic Cancer
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activation and Tif1c inactivation in promoting cystic pancreatic
tumors in our mouse model, we speculated that TIF1c expression
may be down-regulated in human pancreatic tumors. To test this
hypothesis, we analyzed by quantitative RT-PCR the expression
level of TIF1c and SMAD4 mRNA in 20 PDAC and 16
peritumoral tissues coming from surgical specimens removed for
therapeutic purposes (peritumoral tissues were not available for 4
of these patients). The cellularity of the samples used for molecular
analysis was verified histologically. Our results show that TIF1c
expression is significantly decreased in the tumors as compared to
peritumoral tissues (P=0.0054) (Figure 5A). We also compared
TIF1c expression levels in each individual tumor along with the
peritumoral tissue from the same patient (n=16). Our results show
that TIF1c expression is significantly down-regulated in most
patients and is not up-regulated in any patient (Figure 5B). We
next examined TIF1c protein pattern of expression by immuno-
histochemistry in human pancreatic cancers and their precursors.
In peritumoral tissues from PDAC, TIF1c was detected in the
majority of the nuclei of acinar, ductal and endocrine cells
(Figure 5C). Centroacinar cells are more difficult to identify in
routinely stained sections; however, since no epithelial cell
population devoid of TIF1c expression has been detected in the
normal pancreas, it can be assumed that they also express TIF1c.
In PDAC (16 cases), TIF1c nuclear expression level was
significantly decreased as compared to the peritumoral tissue. In
8 cases, TIF1c expression was heterogeneous, with large numbers
of negative cells coexisting with scattered positive cells (Figure 5D).
In 2 cases, TIF1c was even undetectable (Figure 5E). In IPMNs
(samples from 10 patients, all with the intestinal subtype according
to current classifications [3]), almost all neoplastic cells in areas of
low grade dysplasia (present in the 10 cases) displayed a weak
nuclear positivity whereas in areas of high grade dysplasia (present
in the 10 cases), more than 50% of cells were negative for TIF1c;
this was especially the case along the papillary projections
(Figure 5F). In PanINs (samples from 15 patients, with grade 1
in 12, grade 2 in 10 and grade 3 in 8), the expression of TIF1c was
usually retained in grade 1 and 2 lesions (data not shown), but was
undetectable in a variable proportion of cells in grade 3 lesions
(Figure 5G). In MCNs (8 cases), TIF1c protein was strongly
expressed by all neoplastic cells, even in areas of high grade
dysplasia and in foci of microinvasive carcinoma (Figure 5H). We
showed in the same set of tumors that SMAD4 expression was also
down-regulated in high-grade PanINs, IPMNs and PDAC, while
remained highly expressed in MCNs (Figure S4).
None of the Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice (n=4)
sacrificed after the age of 13 weeks showed an aggressive cancer
developed from IPMNs. This observation is consistent with
epidemiological data in humans showing that IPMNs only rarely
give rise to aggressive tumors [3]. Interestingly, IPMNs were
reported in Pdx1-Cre;LSL-Kras
G12D;Smad4
lox/lox mice but no PDAC
was found by the age of 13 weeks (n=8) [21]. Another group
observed in Pdx1-Cre;LSL-Kras
G12D;Smad4
lox/lox a significant pro-
portion of PDAC between 23 and 33 weeks [23]. This suggests
that the minimal latency period to see the onset of aggressive
tumors may have not been reached in our study or the number of
animals studied is too low. We have been in the process of ‘‘aging’’
a cohort of Pdx1-Cre;LSL-Kras
G12D;Tif1c
lox/lox mice to address this
specific point even if we cannot rule out the possibility that these
animals die before developing aggressive tumors because of
pancreatic failure due to growing cysts. The molecular mechanism
supporting the cooperation between activated Kras
G12D mutation
and Tif1c inactivation to induce the formation of IPMNs is still
unknown. TAK1 (TGFb Associated Kinase 1), which has recently
been proposed to explain R-Ras and TGFb cooperation in breast
tumors, is an interesting candidate [36].
The relationship between TIF1c and SMAD4 and their
respective role in TGFb signaling have been a subject of extensive
investigation and debate in the last few years [37]. Indeed,
published data support distinct models whereby TIF1c could
function as either a negative regulator of TGFb signaling [29,30]
or a complementary agonist of TGFb signaling [32]. In the
‘‘antagonist model’’, TIF1c negative function relies on its ability to
mono-ubiquitinate and relocate SMAD4 into the cytoplasm. In
the ‘‘agonist model’’, TIF1c competes with SMAD4 for binding to
SMAD2 and 3 and form TIF1c-SMAD2/3 complexes regulating
SMAD4-independent TGFb responses. One can envision that
these models, both supported by compelling biochemical and in
vivo evidence, are not mutually exclusive and that one of them may
be predominant depending on the cellular context. The experi-
mental evidence we present here suggest that TIF1c works with
SMAD4 as a complementary agonist molecule during pancreatic
tumorigenesis. In the presence of activated Kras, Tif1c loss-of-
function induces cystic lesions resembling those observed in the
absence of Smad4 suggesting that both molecules act in concert to
prevent tumor progression. Even if this hypothesis needs further
demonstration, it is strengthened by the observation that TIF1c
expression is decreased in human pancreatic tumors and our
observation that loss of Tif1c does not significantly impair Smad4
expression level or Smad4 target genes expression (data not shown).
The existence of a joint effort between TIF1c and SMAD4 to
maintain TGFb-mediated tissue homeostasis has been proposed
before. Indeed, during erythroid differentiation, TIF1c mediates
the differentiation response while SMAD4 mediates the antipro-
liferative response [32]. In a recent work, we showed that Tif1c
controlled iNKT (invariant Natural Killer T) cell expansion
whereas Smad4 maintained their maturation state [33]. A recent
comprehensive genetic analysis of .20,000 transcripts in 24
pancreatic cancers failed to identify point mutations, amplifica-
tions, deletion or translocations in the TIF1c gene [20]. The
present study strongly spurs us toward looking for TIF1c genetic
alterations in a larger set of pancreatic tumors. Besides,
chromosomal breakpoints chromosome on 1p13.1 containing
TIF1c gene have been reported in acute megakaryocytic leukemias
[38], osteochondromas [39], bronchial large cell carcinomas [40]
and childhood papillary thyroid carcinomas [41]. Interestingly, we
recently demonstrated that abrogation of the closely related Tif1a
gene in mice caused hepatocellular carcinoma [42]. These
observations reinforce the idea according to which TIF1c loss of
function could play an active protective role during tumorigenesis.
TIF1c overexpression has been suggested by others to facilitate
tumorigenesis in other organs by inhibiting SMAD4-mediated
growth inhibition and motility in response to TGFb [29,30]. This
observation may reflect an active role of TIF1c during tumor
progression depending on the organ and involving a anti-SMAD4
mechanisms (‘‘antagonist’’ model).
In conclusion, we demonstrated in a mouse model that
inactivation of Tif1c cooperates with activated Kras
G12D to induce
cystic pancreatic tumors. Characterization of new players
involved in the outbreak of early pancreatic lesions that will
eventually evolve into invasive pancreatic cancer is crucial to
detect the disease earlier and eventually develop new therapeutic
drugs. Further work to decipher the respective roles of SMAD4
and TIF1c in PDAC as well as the functional cooperation
between KRAS and TIF1c could bring new insight into the
etiology of pancreatic cancer, and generate a better understand-
ing of the multifaceted role of TGFb in carcinogenesis and
development.
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Mice
Tif1c
lox/lox [32] mice harboring floxed exons 2–4 were generated
by K.Y. and R.L. will be described elsewhere. Briefly, using a
genomic clone that contains a portion of the Tif1c gene, we
generated a targeting vector in which a PGK Neo selection cassette
flanked by two loxP sites was introduced into intron 1 and a third
loxP site inserted into intron 4. This targeting vector was designed
with the expectation that upon homologous recombination and
subsequent Cre recombinase-mediated excision, exons 2, 3 and 4
along with the PGK-Neo cassette would be deleted, thereby causing
Figure 5. TIF1c expression in human pancreatic neoplasia. The expression of TIF1c from 20 human PDAC and 16 peritumoral tissues was
determined by quantitative RT–PCR (A). The average expression (6sd) is plotted for each group (B). The significance (P value) for the difference
between peritumoral and tumoral groups, determined by a Student’s T test, is shown above the graphs. The expression of TIF1c protein was
evaluated by immunohistochemistry in different pancreatic lesions: PDAC (n patients=20) (peritumoral (C) and tumoral tissues (D, E). IPMN (n
patients=10) of high grade dysplasia (F), high-grade PanINs (n patients=8) (G) and MCN (n patients=15) (H). Inset pictures: higher magnification.
doi:10.1371/journal.pgen.1000575.g005
TIF1c Mutation and Pancreatic Cancer
PLoS Genetics | www.plosgenetics.org 7 July 2009 | Volume 5 | Issue 7 | e1000575a frameshift mutation with a premature termination codon in exon
5. The putative product of this deleted gene corresponds to a
truncated protein lacking part of the RING finger-B box-coiled
coil (RBCC) motif and the entire C-terminal region of the TIF1c
protein, which contains the conserved PHD finger/bromodomain
unit.
Ink4A/Arf
lox/lox [12], LSL-Kras
G12D [8,43–45] and Pdx1-Cre [34]
mouse strains done by others were previously described. Mice
were maintained in a specific pathogen-free animal facility at the
‘‘Centre Le ´on Be ´rard’’ (Lyon, France) and handled in compliance
with the institutional guidelines. All procedures were approved by
an ethic committee under regulatory of governmental authority
(CREEA).
Histology
Histology experiments were performed as previously described
[46]. Primary antibody used were : TIF1c (1/800; Euromedex),
Chymotrypsin (1/1000; AbD Serotec), Insulin (1/1000; Dako),
CK19 (1/10; Trauma III - Developmental Studies Hybridoma
Bank - University of Iowa), SMAD4 (1/100; Santa Cruz). Alcian
blue staining was performed as previously described [47].
Human samples
Cryopreserved tumoral and peritumoral tissue samples were
obtained from an institutionalt i s s u eb a n k ,t h eT u m o r o t h e `que
des Hospices Civils de Lyon (Centre de Ressources Biologi-
ques, Hospices Civils de Lyon). In accordance with French
ethical rules, samples were from patients having given their
informed consent or from deceased patients. Prior to molecular
analysis, the quality and cellularity of tissue samples was
verified histologically; tumor tissues were selected in order to
contain a significant amount of neoplastic cells; peritumoral
tissues were constantly altered by reactive fibrotic changes
associated with a loss in acinar tissue and a massive ductular
proliferation.
RNA analysis
Liquid nitrogen frozen human tumors were blended using a
Pro200 homogenizer (Pro Scientific Inc.) in a 5 M guanidine
solution. Total RNA was further purified by RNeasy mini kit
(Qiagen). The cDNA was used as template with RT Kit
SuperScript II (Invitrogen). quantitative RT-PCR was performed
as previously described [48].
Live imaging
For MRI and PET experiments, mice were anesthetized using
3% isoflurane inhalation (TEM Sega, Lormont, France) and
maintained in 1.5% isoflurane atmosphere during experiments.
For PET experiments, the mice were catherized in the caudal
vein (24 gauge), injected with 250 mCi of 300 mL of radioactive
18-Fluorode ´oxyglucose (FDG). After 90 minutes to allow FDG
fixation, images were acquired during 15 minutes (constant 2%
isoflurane atmosphere) using the ‘‘TEP clearPET’’ (Raytest,
Inc.). MRI acquisitions were made with a BioSpec-7T system
(Bruker, Ettlingen, Germany) using a 32 mm inner-diameter
emission/reception volume coil (Rapid Biomedical, Wu ¨rzburg,
Germany). T1/T2-weighted contrast sequences synchronized to
respiration were acquired for each mouse. A RARE (Rapid
Acquisition with Relaxation Enhancement) sequence (TR/TE
3500/38.1 ms) with fat saturation was used. Geometric param-
eters were: a series of 18, 750 mm thick sections, 33 mm field of
view, and 2566256 pixel matrix. Voxel size was therefore
12961296750 mm
3.
Supporting Information
Figure S1 Loss of nuclear Tif1c protein expression in the
pancreas of Pdx1-Cre; Tif1c
lox/lox mice. Immunohistochemistry
showed that Tif1c was expressed in the nuclei of pancreatic cells in
wild-type mice and that this staining was lost in a Pdx1-
Cre;TIF1c
lox/lox pancreas.
Found at: doi:10.1371/journal.pgen.1000575.s001 (2.25 MB TIF)
Figure S2 Image of a polycystic pancreas from a 154-day-old
Pdx1-Cre; LSL-Kras
G12D; Tif1c
lox/lox mouse. Pancreas is circled in
black. Note the presence of numerous translucent cysts (arrow-
head).
Found at: doi:10.1371/journal.pgen.1000575.s002 (2.96 MB TIF)
Figure S3 Presence of inflammatory cells in the pancreas
associated with the cystic structures. Immunohistochemistry
revealed the presence of different populations of leucocytes
infiltrating the pancreas of a 20-day-old Pdx1-Cre; LSL-Kras
G12D;
Tif1c
lox/lox mouse (D–F) compared to a wild-type littermate (A–C).
MPO (A,D), F4/80 (B,E), and CD3 (C,F) were respectively used as
specific markers for neutrophiles, macrophages and lymphocytes.
Found at: doi:10.1371/journal.pgen.1000575.s003 (2.71 MB TIF)
Figure S4 SMAD4 expression in human pancreatic neoplasia.
Quantitative RT–PCR to detect SMAD4 expression from the 16
PDAC for which peritumoral tissue was available (A). For each
patient represented by an individual bar, SMAD4 expression is
represented as a percentage of variation relative to mRNA
expression in the peritumoral tissue from the same patient (B).
SMAD4 protein expression pattern was also assessed by
immunohistochemistry. In the normal pancreas (C), SMAD4 is
strongly detected in endocrine islets, a faint labeling is visible in
acinar cells and ductal cells. In adenocarcinomas (n patients=20),
no labeling for SMAD4 was detected whereas adjacent residual
endocrine cells are positive (D). In another example of adenocar-
cinoma, SMAD4 is faintly but readily detectable in neoplastic
cells; the labeling is both cytoplasmic and nuclear (E). In IPMN
grade 3, SMAD4 expression is heterogeneous; most cells are
negative, while a few scattered cells retain a faint expression,
usually nuclear (F). In PanIN grade 3, SMAD4 expression is either
undetectable, as exemplified in the largest figure (note the
persistent expression in adjacent residual endocrine cells (arrow)),
or heterogeneous, as shown in the inset (G). In MCN, SMAD4
expression is usually strong, in low grade (large figure) as well as in
high grade (inset) lesions (H).
Found at: doi:10.1371/journal.pgen.1000575.s004 (3.34 MB TIF)
Table S1 Measurement of the area occupied by the normal
pancreatic tissue.
Found at: doi:10.1371/journal.pgen.1000575.s005 (0.06 MB
DOC)
Acknowledgments
We thank G. Gouysse, J.B. Langlois, S. Martin, M. Janier, P. Meeus, and
M. Peix for their expert assistance. We are deeply grateful to D. Wotton for
advice, helpful discussions, and proofreading of the manuscript. We thank
T. Jacks/R. DePinho, D.Tuveson, and D. Melton for providing Ink4A/
Arf
lox/lox, LSL-Kras
G12D, and Pdx1-Cre mouse strains.
Author Contributions
Conceived and designed the experiments: DFV SM LB. Performed the
experiments: DFV KPY IT FG VA BK FL SM SGL SG JYS RL LB.
Analyzed the data: DFV IT VA BK JCM SM JLI PD SG AP RR NB JYS
RL LB. Contributed reagents/materials/analysis tools: DFV KPY IT VA
JCM NB JYS RL LB. Wrote the paper: RL LB.
TIF1c Mutation and Pancreatic Cancer
PLoS Genetics | www.plosgenetics.org 8 July 2009 | Volume 5 | Issue 7 | e1000575References
1. Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3: 157–188.
2. Maitra A, Fukushima N, Takaori K, Hruban RH (2005) Precursors to invasive
pancreatic cancer. Adv Anat Pathol 12: 81–91.
3. Furukawa T, Kloppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, et
al. (2005) Classification of types of intraductal papillary-mucinous neoplasm of
the pancreas: a consensus study. Virchows Arch 447: 794–799.
4. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A (2008) Pancreatic
carcinogenesis. Pancreatology 8: 110–125.
5. Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nature
Reviews Cancer 2: 897–909.
6. Shi C, Hruban RH, Klein AP (2009) Familial pancreatic cancer. Arch Pathol
Lab Med 133: 365–374.
7. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, et al.
(2006) Pathology of genetically engineered mouse models of pancreatic exocrine
cancer: consensus report and recommendations. Cancer Res 66: 95–106.
8. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, et al. (2003)
Preinvasive and invasive ductal pancreatic cancer and its early detection in the
mouse. Cancer Cell 4: 437–450.
9. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, et al.
(2007) Chronic pancreatitis is essential for induction of pancreatic ductal
adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291–302.
10. Grippo PJ, Nowlin PS, Demeure MJ, Longnecker DS, Sandgren EP (2003)
Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell
targeting of mutant Kras in transgenic mice. Cancer Research 63: 2016–2019.
11. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. (2005)
Trp53R172H and KrasG12D cooperate to promote chromosomal instability
and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:
469–483.
12. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, et al. (2003) Activated
Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic
ductal adenocarcinoma. Genes & Development 17: 3112–3126.
13. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, et al. (2006) Both
p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic
adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 103: 5947–5952.
14. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, et al. (2006) Aggressive
pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade
of transforming growth factor-beta signaling in cooperation with active Kras
expression. Genes Dev 20: 3147–3160.
15. Hezel AF, Gurumurthy S, Granot Z, Swisa A, Chu GC, et al. (2008) Pancreatic
LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell
Biol 28: 2414–2425.
16. Siveke JT, Einwachter H, Sipos B, Lubeseder-Martellato C, Kloppel G, et al.
(2007) Concomitant pancreatic activation of Kras(G12D) and Tgfa results in
cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12:
266–279.
17. De La OJ-P, Emerson LL, Goodman JL, Froebe SC, Illum BE, et al. (2008)
Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial
neoplasia. Proc Natl Acad Sci U S A 105: 18907–18912. Epub 12008 Nov
18921.
18. Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, et al. (2009) GLI1 is
regulated through Smoothened-independent mechanisms in neoplastic pancre-
atic ducts and mediates PDAC cell survival and transformation. Genes Dev 23:
24–36.
19. Shi G, Zhu L, Sun Y, Bettencourt R, Damsz B, et al. (2009) Loss of the Acinar-
Restricted Transcription Factor Mist1 Accelerates Kras-Induced Pancreatic
Intraepithelial Neoplasia. Gastroenterology 136(4): 1368–1378.
20. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling
pathways in human pancreatic cancers revealed by global genomic analyses.
Science 321: 1801–1806.
21. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, et al. (2006) Smad4 is
dispensable for normal pancreas development yet critical in progression and
tumor biology of pancreas cancer. Genes Dev 20: 3130–3146.
22. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, et al. (2007)
Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous
cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11:
229–243.
23. Kojima K, Vickers SM, Adsay NV, Jhala NC, Kim HG, et al. (2007)
Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
Cancer Res 67: 8121–8130.
24. Kuang C, Xiao Y, Liu X, Stringfield TM, Zhang S, et al. (2006) In vivo
disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions
in the pancreas. Proc Natl Acad Sci U S A 103: 1858–1863.
25. Ross S, Hill CS (2008) How the Smads regulate transcription. Int J Biochem Cell
Biol 40: 383–408.
26. Massague J, Gomis RR (2006) The logic of TGFbeta signaling. FEBS Lett 580:
2811–2820.
27. Venturini L, You J, Stadler M, Galien R, Lallemand V, et al. (1999)
TIF1gamma, a novel member of the transcriptional intermediary factor 1
family. Oncogene 18: 1209–1217.
28. Yan KP, Dolle P, Mark M, Lerouge T, Wendling O, et al. (2004) Molecular
cloning, genomic structure, and expression analysis of the mouse transcriptional
intermediary factor 1 gamma gene. Gene 334: 3–13.
29. Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, et al. (2005)
Germ-layer specification and control of cell growth by Ectodermin, a Smad4
ubiquitin ligase. Cell 121: 87–99.
30. Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, et al. (2009)
FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling,
controls Smad4 monoubiquitination. Cell 136: 123–135.
31. Levy L, Howell M, Das D, Harkin S, Episkopou V, et al. (2007) Arkadia
activates Smad3/Smad4-dependent transcription by triggering signal-induced
SnoN degradation. Mol Cell Biol 27: 6068–6083.
32. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, et al. (2006)
Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the
TGFbeta pathway. Cell 125: 929–941.
33. Doisne JM, Bartholin L, Yan KP, Garcia CN, Duarte N, et al. (2009) iNKT cell
development is orchestrated by different branches of TGF-beta signaling. J Exp
Med 206: 1365–1378.
34. Gu G, Dubauskaite J, Melton DA (2002) Direct evidence for the pancreatic
lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors.
Development 129: 2447–2457.
35. Jorgensen MC, Ahnfelt-Ronne J, Hald J, Madsen OD, Serup P, et al. (2007) An
illustrated review of early pancreas development in the mouse. Endocr Rev 28:
685–705.
36. Erdogan M, Pozzi A, Bhowmick N, Moses HL, Zent R (2008) Transforming
growth factor-beta (TGF-beta) and TGF-beta-associated kinase 1 are required
for R-Ras-mediated transformation of mammary epithelial cells. Cancer Res 68:
6224–6231.
37. Heldin CH, Moustakas A (2006) A new twist in Smad signaling. Dev Cell 10:
685–686.
38. Ng YY, Fan JM, Mu W, Nikolic-Paterson DJ, Yang WC, et al. (1999)
Glomerular epithelial-myofibroblast transdifferentiation in the evolution of
glomerular crescent formation. Nephrol Dial Transplant 14: 2860–2872.
39. Sawyer JR, Thomas EL, Lukacs JL, Swanson CM, Ding Y, et al. (2002)
Recurring breakpoints of 1p13 approximately p22 in osteochondroma. Cancer
Genet Cytogenet 138: 102–106.
40. Johansson M, Dietrich C, Mandahl N, Hambraeus G, Johansson L, et al. (1994)
Karyotypic characterization of bronchial large cell carcinomas. Int J Cancer 57:
463–467.
41. Klugbauer S, Rabes HM (1999) The transcription coactivator HTIF1 and a
related protein are fused to the RET receptor tyrosine kinase in childhood
papillary thyroid carcinomas. Oncogene 18: 4388–4393.
42. Khetchoumian K, Teletin M, Tisserand J, Mark M, Herquel B, et al. (2007) Loss
of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid
receptor alpha. Nat Genet 39: 1500–1506.
43. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis
of lung tumor initiation and progression using conditional expression of
oncogenic K-ras. Genes & Development 15: 3243–3248.
44. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. (2001)
Somatic activation of the K-ras oncogene causes early onset lung cancer in
mice.[see comment]. Nature 410: 1111–1116.
45. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, et al. (2004)
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread
neoplastic and developmental defects. Cancer Cell 5: 375–387.
46. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, et al.
(2004) Dendritic cell infiltration and prognosis of early stage breast cancer. Clin
Cancer Res 10: 7466–7474.
47. Albores-Saavedra J, Weimersheimer-Sandoval M, Chable-Montero F, Mon-
tante-Montes de Oca D, Hruban RH, et al. (2008) The foamy variant of
pancreatic intraepithelial neoplasia. Ann Diagn Pathol 12: 252–259.
48. Bartholin L, Cyprian FS, Vincent D, Garcia CN, Martel S, et al. (2008)
Generation of mice with conditionally activated transforming growth factor beta
signaling through the TbetaRI/ALK5 receptor. Genesis 46(12): 724–731.
TIF1c Mutation and Pancreatic Cancer
PLoS Genetics | www.plosgenetics.org 9 July 2009 | Volume 5 | Issue 7 | e1000575